An updated scoring system for prediction of survival after resection of colorectal liver metastases: addition of KRAS status as an important risk modifier.
作者信息
Jost Evan, Major Don, Dixon Elijah
机构信息
Department of Hepatobiliary Surgery, University of Calgary, Calgary, Canada.
出版信息
Hepatobiliary Surg Nutr. 2020 Feb;9(1):70-72. doi: 10.21037/hbsn.2019.06.06.
Abstract
摘要
相似文献
1
An updated scoring system for prediction of survival after resection of colorectal liver metastases: addition of KRAS status as an important risk modifier.一种用于预测结直肠癌肝转移切除术后生存率的更新评分系统：将KRAS状态作为重要风险修正因素纳入其中。
Hepatobiliary Surg Nutr. 2020 Feb;9(1):70-72. doi: 10.21037/hbsn.2019.06.06.
2
KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases.KRAS 突变与结直肠癌肝转移患者的转移性进展加速相关。
Ann Surg Oncol. 2010 Feb;17(2):572-8. doi: 10.1245/s10434-009-0605-3. Epub 2009 Sep 1.
3
A new scoring system to classify patients with colorectal liver metastases: proposal of criteria to select candidates for hepatic resection.一种用于对结直肠癌肝转移患者进行分类的新评分系统：选择肝切除候选者的标准建议。
J Hepatobiliary Pancreat Surg. 2004;11(2):79-83. doi: 10.1007/s00534-002-0778-7.
4
Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases.结直肠癌肝转移切除术后 KRAS 突变与生存的荟萃分析。
Br J Surg. 2015 Sep;102(10):1175-83. doi: 10.1002/bjs.9870. Epub 2015 Jul 21.
5
Prognostic impact of K-RAS mutational status and primary tumor location in patients undergoing resection for colorectal cancer liver metastases: an update.结直肠癌肝转移患者接受切除术治疗时，K-RAS 基因突变状态和原发肿瘤位置的预后影响：一项更新。
Future Oncol. 2019 Sep;15(27):3149-3157. doi: 10.2217/fon-2019-0196. Epub 2019 Aug 20.
6
The association of KRAS mutation with primary tumor location and survival in patients undergoing resection of colorectal cancers and synchronous liver metastases.KRAS突变与接受结直肠癌切除及同期肝转移灶切除患者的原发肿瘤位置和生存率的相关性。
Chin Clin Oncol. 2019 Oct;8(5):46. doi: 10.21037/cco.2019.08.10. Epub 2019 Sep 2.
7
Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis.KRAS 和 BRAF 基因突变对肝切除术后转移性结直肠癌患者生存的影响：系统评价和荟萃分析。
Clin Colorectal Cancer. 2017 Sep;16(3):e153-e163. doi: 10.1016/j.clcc.2017.01.004. Epub 2017 Jan 25.
8
Chemotherapy Plus Cetuximab versus Chemotherapy Alone for Patients with KRAS Wild Type Unresectable Liver-Confined Metastases Colorectal Cancer: An Updated Meta-Analysis of RCTs.化疗联合西妥昔单抗与单纯化疗治疗KRAS野生型不可切除的局限于肝脏的转移性结直肠癌患者：随机对照试验的最新Meta分析
Gastroenterol Res Pract. 2017;2017:8464905. doi: 10.1155/2017/8464905. Epub 2017 Jan 11.
9
Prognostic impact of and mutations in patients who underwent simultaneous resection for initially resectable colorectal liver metastases.同时切除初始可切除的结直肠癌肝转移患者中[具体基因]和[具体基因]突变的预后影响
Int J Clin Exp Pathol. 2018 Dec 1;11(12):5981-5991. eCollection 2018.
10
Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.KRAS、BRAF、PI3K和TP53基因突变分析对可切除和不可切除结直肠癌肝转移的临床意义及预后相关性：当前证据的系统评价
Surg Oncol. 2018 Jun;27(2):280-288. doi: 10.1016/j.suronc.2018.05.012. Epub 2018 May 8.
本文引用的文献
1
Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.KRAS、BRAF、PI3K和TP53基因突变分析对可切除和不可切除结直肠癌肝转移的临床意义及预后相关性：当前证据的系统评价
Surg Oncol. 2018 Jun;27(2):280-288. doi: 10.1016/j.suronc.2018.05.012. Epub 2018 May 8.
2
RAS Mutation Clinical Risk Score to Predict Survival After Resection of Colorectal Liver Metastases.RAS 基因突变临床风险评分预测结直肠癌肝转移切除术后的生存。
Ann Surg. 2019 Jan;269(1):120-126. doi: 10.1097/SLA.0000000000002319.
3
Resection of Liver Metastases in Colorectal Cancer in the Era of Expanding Systemic Therapy.结直肠癌肝转移切除术在系统治疗拓展时代。
Annu Rev Med. 2017 Jan 14;68:183-196. doi: 10.1146/annurev-med-062415-093510. Epub 2016 Sep 28.
4
RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases.RAS突变可预测在结直肠肝转移灶切除术前接受化疗的患者的放射学和病理学反应。
Ann Surg Oncol. 2015 Mar;22(3):834-842. doi: 10.1245/s10434-014-4042-6. Epub 2014 Sep 17.
5
Food and Drug Administration approval of cetuximab and a new KRAS genetic test for metastatic colorectal cancer: major advance but just the tip of the biomarker iceberg.
Am J Ther. 2012 Nov;19(6):395-6. doi: 10.1097/MJT.0b013e31826a94d8.
6
Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.预测转移性结直肠癌肝切除术后复发的临床评分：1001例连续病例分析
Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21. doi: 10.1097/00000658-199909000-00004.
7
Major hepatic resection for metachronous metastases from colon cancer.结肠癌异时性转移灶的肝大部切除术
Ann Surg. 1985 Feb;201(2):204-9. doi: 10.1097/00000658-198502000-00012.
Zotero 插件